NRG GY012

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Endometrial Metastatic, Gynecologic

Status:

New, Temporarily Closed

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

NCT#03660826

NRG-GY012 will suspend to accrual effective 02/04/19 due to a planned formal safety review.